Does your personal clinical experience confirm what we know from the ocrelizumab efficacy and safety from the 11 years data?

 
 
 

What would be your main driver to start treatment with ocrelizumab in a treatment-naive patient?

 
 
 

After 11 years of ocrelizumab use, can you please elaborate about the risk of infections and particularly serious infections for patients who receive ocrelizumab for a long term?

 
 
 

Today, with the long term data and experience of high efficacy treatment early use, what would you say to those healthcare professionals who still choose the escalation treatment paradigm?

 
 
 

How can family and therapy planning be optimally combined?

 
 
 

 

מוגש מטעם חברת רוש
למידע מלא יש לעיין בעלון התכשיר במאגר התרופות שבאתר משרד הבריאות.